662 results about "Use medication" patented technology

The invention relates to application of a combined pharmaceutical composition in preparation of a medicine for resisting transforming follicular lymphoma. Active components in the combined pharmaceutical composition comprise a first component and a second component, the first component is selected from any one or a combination of at least two of sitagliflozin, pharmaceutically acceptable salt, isomer, solvate and metabolite of sitagliflozin; and the second component is selected from any one or a combination of at least two of chidamide, pharmaceutically acceptable salts, isomers, solvates and metabolites of the chidamide. Research finds that the combined use of the two active components not only can reduce the dosage of each drug and improve the medication safety, but also has the effect of improving or treating convertible follicular lymphoma more remarkably than that of a single drug active component, and plays a role in synergistic promotion. The invention provides an effective drug combination strategy for improvement or treatment of convertible follicular lymphoma, and has very significant significance.

The invention discloses a drug-combined anticancer composition and application of the composition in preparation of anticancer drugs. According to the present invention, the drug combination composition comprises the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate, the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate provide the synergistic effect, and compared with the single PARP inhibitor, the drug combination composition has characteristics of high stomach cancer sensitivity, significant gastric cancer efficiency improving, and wide application prospect. The Amlodipine in the drug combination composition provided by the invention enhances the curative effect of the PARP inhibitor Olaparib on the gastric cancer.

The invention discloses an application of a CYP3A4 * 1G gene in preparation of a product for evaluating the postoperative analgesic effect and dosage prediction of sufentanil compounded with butorenol. According to the invention, the gene polymorphism of CYP3A4 * 1G is found to be one of genetic factors causing sufentanil compounded butornori postoperative analgesic effect and dosage use difference individualized difference for the first time, and anesthetists can determine the dosage of analgesic drugs for postoperative patients according to genetic characteristic difference, so that the satisfaction degree of anesthesia and postoperative analgesia of the patients is improved; therefore, the CYP3A4 * 1G gene can be used as a marker for evaluating the postoperative analgesic effect and dosage use of sufentanil compounded with butoenorphan, and detection is carried out through related genes of postoperative analgesic medication of a patient and CYP3A4 * 1G genotyping, so that guidance can be provided for the postoperative analgesic medication dosage of the patient.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

The invention discloses an icaritin carbamate prodrug as well as a preparation method and application thereof, belongs to the field of pharmacy, and particularly relates to an icaritin carbamate prodrug as shown in a formula 3-N or 7-N and pharmaceutically acceptable salts thereof as well as a preparation method and application of the icaritin carbamate prodrug. Specifically, a main metabolic site (3-site or 7-site hydroxyl) of a natural flavone compound icaritin is subjected to structural modification through a chemical synthesis method, and an appropriate group is introduced into the site to form the icaritin carbamate prodrug. Amines adopted by the carbamate are aliphatic amines. Due to existence of a carbamate structure, II-phase metabolism of icaritin in SD rats is reduced, compared with icaritin raw material medicine, the 3-N-01 prodrug has the advantages that oral bioavailability is remarkably improved, the 3-N-01 prodrug is the optimal prodrug, clinical medication is expected to be capable of reducing administration dosage and improving patient compliance, and the 3-N-01 prodrug can be applied to preparation of the SD rats. And an effective strategy is expected to be provided for improving the oral bioavailability of phenolic drugs. # imgabs0 #

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

The invention relates to the technical field of pharmaceutical preparations, in particular to a docetaxel oral self-microemulsion composition and a preparation process thereof. The docetaxel oral self-microemulsion composition is prepared from docetaxel, an oil phase, a surfactant, a cosurfactant, a stabilizer and an antioxidant, the oil phase is caprylic / capric acid mono / diglyceride, medium chain triglyceride, caprylic acid propylene glycol ester or lauric acid propylene glycol ester. The docetaxel oral self-microemulsion composition provided by the invention has relatively high drug loading capacity, good physical and chemical stability and relatively high bioavailability, and is more suitable for clinical medication.

According to the nitrogen hydrochloride # imgabs0 # stine eye drops for treating allergic conjunctivitis and the preparation method of the nitrogen hydrochloride # imgabs0 # stine eye drops, the prepared eye drops can interact with the mucous layer on the surface of keratoconjunctiva by selecting specific solid lipid and a surfactant and controlling the dosage of the solid lipid and the surfactant; the retention capacity of the medicine in front of the cornea is prolonged, so that the medicine has good targeting property, the continuous release of the medicine is realized, the medication frequency can be reduced, the toxic and side effects of the medicine are reduced, the bioavailability is improved, the medication compliance of a patient is enhanced, and in the preparation and long-term storage processes, the medicine has better stability, and is suitable for popularization and application. Therefore, the problems of excessive drug due to multiple administration and poor stability of the active component nitrogen hydrochloride # imgabs1 # stine are solved.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention discloses an application of indolepropionic acid in preparation of a medicine for preventing or treating ovarian cancer, the medicine takes indolepropionic acid as an active ingredient, the concentration is 0.1-1000 mu M, and the dosage forms comprise tablets, capsules, granules, pills, gels, suppositories, ointments, emulsions, mixtures, suspensions, injections and solutions. Administration routes comprise oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration, and can be combined with chemotherapeutic drugs for use. It is found through experiments that IPA with different concentrations can inhibit cell growth of ovarian cancer cell lines SKOV3 and A2780, cell proliferation of macrophages RAW264.7 is remarkably promoted, and the IPA has a potential immune promotion effect and good biological safety. In addition, the IPA can enhance the sensitivity of chemotherapeutic drugs, and the IPA and the chemotherapeutic drugs are combined to be applied to treatment of ovarian cancer, so that the treatment effect of the drugs can be remarkably improved.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to astragalus membranaceus and rhizoma polygonati oral liquid and a preparation method thereof. The invention provides a radix astragali and rhizoma polygonati oral liquid. The radix astragali and rhizoma polygonati oral liquid comprises the following components in parts by weight: 25-35 parts of radix astragali, 25-35 parts of rhizoma polygonati, 25-35 parts of radix asteris and 10-25 parts of radix codonopsis which are used as monarch drugs; 10-20 parts of bighead atractylodes rhizome, 25-35 parts of poria cocos, 25-35 parts of prepared rehmannia root and 15-20 parts of caffeoyl butanediamine which are used as ministerial drugs; 10-20 parts of angelica sinensis, 25-35 parts of fructus lycii and 10-20 parts of herba ecliptae are used as adjuvant drugs; and 5-10 parts of honey-fried licorice root and 10-20 parts of glossy privet fruit as conductant drugs. According to the monarch, minister, assistant and guide medication idea of traditional Chinese medicine, caffeoyl butanediamine is matched, so that the oral liquid can effectively tonify qi and enrich blood, exert the curative effect of tonifying qi and boost the spirit of a patient, and has good social benefits.

Disclosed in the present invention is a compound represented by formula (I), or a pharmaceutically acceptable salt, ester or solvate thereof. Such a PSMA compound has higher tumor uptake and / or lower or substantially equivalent kidney uptake, can improve the drug targeting effect and / or reduce the kidney injury risk, and is conducive to better meeting the medication needs of patients.

The invention discloses a 2, 5-diketopiperazine compound with an anti-tumor effect and application of the 2, 5-diketopiperazine compound in preparation of a medicine for treating and / or preventing neutropenia, and the 2, 5-diketopiperazine compound is novel in structure, has good activity and water solubility, and can be used for preparing medicines for treating and / or preventing neutropenia. The defects of poor water solubility of the ponabulin, unfavorable patent medicine and difficult clinical administration can be overcome. The 2, 5-diketopiperazine compound as shown in the formula (I) or the pharmaceutically acceptable salt thereof can be used for treating and / or preventing neutropenia and improving toxic and side effects of clinical tumor treatment, and has an anti-tumor effect at the same time. The invention also discloses application of drug combination of the compound and a granulocyte colony stimulating factor (G-CSF) biological agent in drugs for treating and / or preventing neutropenia. # imgabs0 #

The invention provides a preparation method and application of a suspension containing a PDE-4 or PDE-3 / 4 inhibitor for sterile inhalation. The preparation method comprises the following steps: dispersing a PDE-4 or PDE-3 / 4 inhibitor in injection water containing an excipient, and carrying out high-pressure moist heat sterilization to obtain a PDE-4 or PDE-3 / 4 inhibitor dispersion liquid; dissolving the long-acting beta2-receptor stimulant and / or the long-acting muscarinic receptor antagonist, sterilizing and filtering to obtain a mixed solution; and mixing the PDE-4 or PDE-3 / 4 inhibitor dispersion liquid with the mixed solution, dispersing, and carrying out sterile filling. The medicinal preparation prepared by the invention is a sterile inhalation suspension, and the sterile inhalation suspension containing the PDE-4 or PDE-3 / 4 inhibitor is high in bioavailability, good in patient medication compliance and good in preparation stability.

The invention provides application of combined use of baicalin and magnesium ions in preparation of nasal cavity medicines for treating cerebral apoplexy. The invention also provides a pharmaceutical composition for treating cerebral apoplexy. The bioavailability of baicalin and magnesium ions in the brain is improved. Magnesium ions can block calcium ions and inhibit glutamic acid excitatory toxicity in the stroke incidence process, and baicalin has multiple biological activities such as inflammation resistance, oxidation resistance and neuroprotection. Experiments prove that the combined application of magnesium ions and baicalin prolongs the survival time, neurological scoring, weight recovery and behavioral improvement of cerebral apoplexy model mice; when the two medicines are combined for use, after respective dosages are halved, the treatment effect on cerebral apoplexy is stronger than that of a single medicine.

The invention discloses application of a nitroimidazole derivative and a combined drug in preparation of a drug for resisting drug-sensitive tuberculosis, and belongs to the technical field of biological medicine. The invention provides application of a nitroimidazole derivative and a combined drug in preparation of a drug for resisting drug-sensitive tuberculosis in order to solve the clinical research blank of the nitroimidazole derivative in prevention and treatment of drug-sensitive tuberculosis. Animal experiments, I-stage clinic, II-stage clinic and medication dosage and mode optimization prove that the nitroimidazole derivative has no obvious drug accumulation, no obvious reproductive toxicity, no obvious cardiotoxicity and no QT interval extension, and compared with existing drugs such as deramanib, the nitroimidazole derivative is shorter in treatment time, more remarkable in curative effect, higher in safety and suitable for clinical application. Especially in lung iconography, voids of a patient are obviously reduced or focuses are obviously absorbed, so that the compound is expected to be used as a new medicine for preventing and treating drug-sensitive pulmonary tuberculosis.

The invention provides an inhalation medication auxiliary device, relates to the technical field of medical instruments, and solves the technical problem that a large force is needed when a puncture part of an inhaler is pressed to puncture a capsule. The inhalation medication auxiliary device comprises a shell and an automatic puncturing module, and the shell covers an inhaler and is used for fixing the inhaler; the automatic puncturing module is arranged on the shell and used for automatically puncturing the capsule placed in the inhaler. According to the embodiment of the invention, the automatic puncturing of the capsule in the inhaler is realized through the automatic puncturing module arranged on the shell, so that the technical problems that large force is needed when the puncturing part of the inhaler is pressed to puncture the capsule, a user with weak force is difficult to press, and the inhaler is not friendly to old and young users are solved.

Provided are a sustained-release microsphere for polypeptide drugs, a pharmaceutical formulation thereof, a method for preparing same, and use thereof. The method comprises the following steps: forming an inner aqueous phase; forming an oil phase; forming an outer aqueous phase; and dispersing the inner aqueous phase into the oil phase to give a primary emulsion, then re-dispersing the primary emulsion into the outer aqueous phase to give a pre-secondary emulsion, emulsifying the pre- secondary emulsion to form a secondary emulsion, and finally curing the secondary emulsion to give the sustained-release microsphere. The method features ease to operate, and the obtained sustained-release microsphere possesses ideal drug release behaviors (low early burst release, and stable mid- and later-stage releases) and safety and potency in reducing blood glucose, and is thus suitable for stable, long-term use with good patient compliance.

The invention provides a tetrahydropyridine derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the tetrahydropyridine derivative, application of the tetrahydropyridine derivative as a muscarinic receptor agonist and application of the tetrahydropyridine derivative in preparation of drugs for treating pain and central mental system disorders or / and diseases related to the pain and the central mental system disorders. The compound provided by the invention has the advantages of high selectivity to muscarinic receptors, no sex difference of pharmacokinetic parameters, small adverse reaction to gastrointestinal tracts, higher drug safety window, higher drug safety and lower clinical dosage.

The invention belongs to the technical field of biological medicines, and particularly relates to application of quercetin combined with curcumin in preparation of an anti-allergic reaction medicine. Through a large number of researches, the inventor finds that combined administration of quercetin and curcumin with a specific concentration can effectively inhibit mast cell degranulation, and the inhibition rate of mast cell degranulation reaches 90% or more, so that I-type anaphylaxis mediated by immune globulin E is inhibited, especially systemic anaphylaxis, and the curative effect is good. The compound can be used for preparing anti-anaphylaxis drugs. The drug combination scheme provided by the invention has important significance and wide application prospect in drugs for treating or preventing anaphylactic reactions.

The invention relates to the technical field of drug analysis and detection, and particularly discloses a method for detecting the residual quantity of glucose in an irinotecan hydrochloride liposome injection. According to the method, irinotecan hydrochloride in the liposome is fully separated from small molecular substances such as glucose and sodium chloride by adopting an ultrafiltration method, then, a Waters XBridge BEH HILIC chromatographic column is adopted, a mixed solution of an acetate buffer solution with the pH value of 3.8-4.2 and acetonitrile is used as a mobile phase, and the content of irinotecan hydrochloride in the liposome is detected in an isocratic elution mode by adopting a high performance liquid chromatography method. The effective separation of glucose, sodium chloride, 4-hydroxyethylpiperazine, sucrose octasulfate potassium and other substances is realized, and the condition of the glucose residue in the irinotecan hydrochloride liposome is accurately detected. The invention provides a reliable guarantee for improving and better controlling the quality of the irinotecan hydrochloride liposome injection product, and has very important significance for improving the medication safety.

The present application relates to a pharmaceutical combination of a PARP7 inhibitor combined medication, and a use thereof in treating tumors. The pharmaceutical combination comprises: a first active ingredient PARP7 inhibitor, a second active ingredient CTLA-4 inhibitor or platinum complex, and optionally a third active ingredient PD-1 inhibitor or PD-L1 inhibitor.

The invention relates to a pharmaceutical composition for treating pancreatic cancer, and belongs to the technical field of biological medicines. The mass ratio of the resveratrol to the glucosamine is (2.28 mg-45.6 mg): (179.17 mg-895.85 mg), and the pharmaceutical composition group is applied to preparation of products for treating pancreatic cancer or preventing pancreatic cancer metastasis. Compared with a single medication group, the combined application of the resveratrol and the glucosamine has the advantages that the metastasis and invasion capability of pancreatic cancer cells can be more obviously inhibited, and the influence on normal cells is smaller. Researches show that the resveratrol realizes an anti-tumor effect by inhibiting the expression of a ligand in a TGF-beta (Transforming Growth Factor-beta) pathway; and the glucosamine inhibits N-glycosylation modification and further inhibits the stability of a receptor in a TGF-beta pathway so as to realize an anti-tumor effect. And a synergistic interaction effect is achieved through multiple targets on the same path. Therefore, the method has good practical application value.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a new application of a Homai black-bone chicken Baifeng pill in preparation of a medicine for treating premature ovarian failure. According to the invention, a chemotherapy-induced premature ovarian failure rat model is established by intraperitoneal injection of cis-platinum, an immune premature ovarian failure mouse model is established by subcutaneous multi-point injection of mouse zona pellucida polypeptide 3 (pZP3), and the influence of Jianjing black-bone chicken Baifeng pills on animal estrus cycles, visceral organ coefficients, serum sex hormone levels and ovarian histopathologic changes of the two models is observed. The treatment effect of the Hoojing black-bone chicken Baifeng pill on the premature ovarian failure is verified and defined, the new clinical application of the medicine is expanded, and a new treatment medicine and means are provided for treating the premature ovarian failure, so that a technical support is provided for clinical precise medication.

The invention relates to a medicine composition for treating inflammatory bowel disease, a medicine combination and application thereof. The pharmaceutical composition is prepared from inulin and fucoidin, the medicine combination comprises a first medicine preparation and a second medicine preparation, the active ingredient of the first medicinal preparation is inulin; the active ingredient of the second medicinal preparation is fucoidin. The pharmaceutical composition disclosed by the invention can effectively balance the level of proinflammatory and anti-inflammatory factors in a body, remarkably reduce and control intestinal inflammation, enhance the barrier function of intestinal tracts and relieve oxidative stress injury of tissues, can be used for preventing and treating inflammatory bowel diseases, is high in safety and is suitable for being taken for a long time. The medicine combination can provide self-selection of medicines, is convenient for patients to take medicines, and improves the dependency of the patients.

The invention provides the aprepitant and palonosetron hydrochloride compound emulsion for injection, the compound emulsion has better stability, nausea and vomiting can be more conveniently and effectively prevented and treated, and the medication compliance of patients is improved.

Provided is a method for reducing the level of an α2 adrenergic receptor agonist in the body of a patient. Also provided is a method to prevent or treat an overdose in a patient from an α2 adrenergic receptor agonist patient, alone or in combination with another drug of abuse.

Provided are a ginsenoside F1 nasal mucosa formulation and a preparation method therefor and use thereof. The ginsenoside F1 nasal mucosa formulation is prepared using ginsenoside F1 as an active ingredient, together with a nasal mucosa absorption promoter and water, and optionally contains borneol and a bacteriostatic agent. The ranges of the mass percentage of the components are preferably as follows: 0.4-15% of ginsenoside F1, 0-0.8% of borneol, 0.05-40% of the absorption promoter, and 0-0.3% of the bacteriostatic agent. The nasal formulation can be used for treating senile dementia and can improve and restore memory. The nasal solution has the following advantages: improving the solubility of the ginsenoside F1 in water and thereby significantly improving the bioavailability of systemic absorption of ginsenoside F1, and enabling increase in the concentration of ginsenoside F1 in the intracerebral focus by means of formula adjustment according to therapeutic requirements and thereby significantly improving the therapeutic effect for diseases and the safety of drug use.

The present invention relates to the field of chemical medicine, and provides a treprostinil derivative represented by formula I, an isomer or a pharmaceutically acceptable salt thereof, and each group is defined in the specification. The compound as shown in the formula I, the isomer or the pharmaceutically acceptable salt thereof can stay in the lung for a long time and slowly release treprostinil with an effective concentration after being administered through the lung, and can be used for treating pulmonary hypertension diseases and pulmonary fibrosis diseases. The compound as shown in the formula I and the isomer or pharmaceutically acceptable salt thereof provided by the invention are administered through lungs, so that the administration dosage can be greatly reduced, lower administration frequency and wider treatment window can be provided, systemic side effects and local lung irritation can be reduced, and the safety of medicines and the medication tolerance of patients can be greatly improved; and a new treatment choice is provided for patients with pulmonary hypertension and pulmonary fibrosis. # imgabs0 #

The invention relates to an ophthalmic composition in an aqueous solution form. The ophthalmic composition consists of cyclosporine, medium chain triglyceride, polyoxyethylene (40) hydrogenated castor oil, polyethylene glycol 400, glycerol, sodium acetate and water. The pH value of the ophthalmic composition is close to that of tears, and the ophthalmic composition is good in medication comfort and good in stability during storage.